Search clinical trials for: Pimecrolimus cream

Total 1397 results

Actavis Inc.

Completed

Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Glenmark Pharmaceuticals Ltd. India

Completed

Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Mylan Inc.
DPT Laboratories, Ltd.

Completed

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States, Dominican Republic, Honduras
Technische Universität Dresden

Completed

Comparison of Atrophogenic Effect of Hydrocortison 1% Cream and Pimecrolimus 1% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHz Ultrasound of Uninvolved Skin in Patients With Atopic Dermatitis (OCT-AD)

Atopic Dermatitis

Germany
Par Pharmaceutical, Inc.

Completed

Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis
Technische Universität Dresden

Completed

Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound (OCT)

Healthy

Germany
Children's Hospital of Michigan
Novartis Pharmaceuticals

Terminated

Study of Pimecrolimus Treatment for Atopic Dermatitis of African American Children

Atopic Dermatitis
LEO Pharma

Completed

A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Germany
University of Utah
Novartis

Completed

Pimecrolimus Cream for Oral Lichen Planus

Oral Lichen Planus

United States
Children's Hospital of Philadelphia
Novartis Pharmaceuticals

Completed

Combination Therapy for Atopic Dermatitis

Atopic Dermatitis

United States
LEO Pharma

Completed

A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

Atopic Dermatitis

Canada, Israel
Mylan Inc.
Medicine Meda Pharmaceutical Information Consultancy (Beijing) Co., Ltd.

Completed

Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China
Novartis

Completed

Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

Chronic Hand Dermatitis
St Joseph University, Beirut, Lebanon

Unknown

Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

Pityriasis Alba

Lebanon
Novartis

Completed

Reconstitution With Pimecrolimus Cream 1% of Steroid-damaged Skin in Adults With Atopic Dermatitis

Atopic Dermatitis

Germany
Novartis

Completed

Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

Atopic Dermatitis

Philippines
Pfizer

Terminated

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Atopic Dermatitis

United States, Poland, Germany, United Kingdom, Italy, Sweden, Switzerland
Centre Hospitalier Universitaire de Nice

Terminated

Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream

Oral Erosive Lichen Planus
Graceway Pharmaceuticals, LLC

Completed

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Genital Warts

United States
Novartis

Completed

A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis

Atopic Eczema

South Africa
Children's Hospital of Philadelphia
Novartis Pharmaceuticals

Completed

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

Netherton Syndrome

United States
Novartis

Completed

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Amorepacific Corporation

Completed

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

Atopic Dermatitis
Astellas Pharma Inc

Completed

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis

Dermatitis, Atopic

United States
Astellas Pharma Inc

Completed

Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis

Dermatitis, Atopic

United States
Frankel, Amylynne, M.D.
Onset Therapeutics, Inc

Completed

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

Eczema | Atopic Dermatitis

United States
Astellas Pharma Inc

Completed

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

Dermatitis, Atopic

United States, Canada
Center for Vulvovaginal Disorders
Novartis

Completed

Clobetasol Versus Pimecrolimus for Vulvar Lichen Sclerosus

Lichen Sclerosus

United States
Shahid Beheshti University of Medical Sciences

Completed

Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus

Discoid Lupus Erythematosus

Iran, Islamic Republic of
Ceragenix Pharmaceuticals

Completed

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
University of North Carolina, Charlotte
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (MSSkin)

Multiple Sclerosis

United States
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Cutaneous Lichen Planus

United States, Canada
Incyte Corporation

Recruiting

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN1)

Prurigo

United States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
Edesa Biotech Inc.
JSS Medical Research Inc.

Active, not recruiting

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

Allergic Contact Dermatitis

United States, Canada
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
Incyte Corporation

Completed

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Canada
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Lichen Sclerosus

United States, Canada
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2)

Prurigo Nodularis

Spain, Korea, Republic of, United States, Poland, Italy, Austria, Germany, Canada, Switzerland, Australia, France, Denmark, Bulgaria
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)

Dermatitis, Atopic

United States, Canada, Japan
GlaxoSmithKline

Completed

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Psoriasis

United States, Canada, Japan
University Hospital, Ghent

Completed

Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) (Koebner)

Vitiligo

Belgium
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
Medical University of Silesia

Completed

Myorelaxant Effect of Cannabis Cream Topical Skin Application in Patients With TMD

Cannabis | Myofascial Pain | Temporomandibular Disorder | Electromyography

Poland
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
One World Cannabis Ltd.

Completed

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

Safety Study for Future Treatment of Psoriasis

Israel
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia

3

Subscribe